Edition:
United Kingdom

FDA Approves Firdapse For The Treatment Of Lambert-Eaton Myasthenic Syndrome


Thursday, 29 Nov 2018 

Nov 29 (Reuters) - Catalyst Pharmaceuticals Inc ::FDA APPROVES FIRDAPSE® (AMIFAMPRIDINE) FOR THE TREATMENT OF LAMBERT-EATON MYASTHENIC SYNDROME (LEMS).CATALYST PHARMACEUTICALS INC - FIRDAPSE IS EXPECTED TO BE COMMERCIALLY AVAILABLE EARLY IN Q1 OF 2019.